Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

by

in

Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform

ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets

ROCHESTER, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) — Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, announces that it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein targets.

Within the last 3 months, Vaccinex has entered into new antibody discovery agreements for complex targets with 3 major pharma and biotech companies as well as 5 strategic relationships with other antibody service providers who have developed transgenic animal species for immunization or very large synthetic antibody libraries that complement our own technology. ActivMAb’s new “Antigen Virus” application is a powerful complement to drug discovery strategies targeting complex protein targets including ion channels and G-protein coupled receptors (GPCRs) such as chemokine receptors. Specific membrane targets are also key to development of antibody drug conjugates (ADC) for cancer, The ActivMAb system enables expression of functional, properly folded complex proteins on the relatively simple membrane of a mammalian virus. We believe that this is a much more highly purified presentation and efficient selection technology than the complex natural membrane fragments that have been termed virus-like particles.

“We have recently publicized success in selecting high value antibodies against challenging multi-pass membrane targets. We are excited to be able to capitalize on what we believe is recognition of the unique capabilities of our …

Full story available on Benzinga.com


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *